Immunic Inc (NASDAQ:IMUX) is set to participate in key events in February. On February 8, CEO Daniel Vitt and VP Jessica Breu will attend BioCapital Europe 2024 in Amsterdam, engaging in one-on-one investor meetings. To schedule, use the BioCapital conference portal or contact Jessica Breu.
From February 29 to March 2, Immunic will present two accepted abstracts at the ACTRIMS Forum 2024 in West Palm Beach, FL. The poster presentations will be available on the company's website.
Immunic focuses on developing oral, small molecule therapies for chronic inflammatory and autoimmune diseases.